PETACH TIKVA, Israel I August 28, 2013 I Can-Fite BioPharma (TASE: CFBI) (PINKSHEETS: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it will initiate a its Phase 2 study in the U.S., Europe and Israel for its anti-cancer drug CF102 in the treatment of primary liver cancer (hepatocellular carcinoma, or HCC). CF102 is the second drug in the Company’s pipeline of A3 adenosine receptor ligands.
Based on the successful conclusion of a former Phase 1/2 trial, the Company developed a Phase 2 protocol that will be conducted under an open Investigational New Drug (IND) with the U.S. Food and Drug Administration. CF102 has Orphan Drug Designation from the FDA for the treatment of hepatocellular carcinoma (primary liver cancer).The study will include 130 patients with advanced liver cancer, with CF102 given as a standalone drug.
According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2 billion by 2015.
Data from the Phase 1/2 study were published recently in The Oncologist, one of the leading journals in this field, and will be presented in the 18th World Congress on Advances in Oncology. The Company reported that the Phase 1/2 study data demonstrated that the trial objectives were successfully achieved, demonstrating a very favorable safety profile for CF102 in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis classes A and B. In addition, the median overall survival time was very encouraging given that most patients were treated in the second-line setting and some were Child-Pugh class B. Another finding indicated that the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict the patients’ reaction to treatment with CF102. Interestingly, one of the patients that has been included in the Phase 1/2 study is treated for 4 years with CF102 and is doing very well.
About CF102
CF102 is a small orally bioavailable drug which binds with high affinity and selectivity to the A3 adenosine receptor. The latter is highly expressed in tumor cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. CF102 induces a robust anti-tumor effect via de-regulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells.
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American Depository Receipts of the company are traded on the over-the-counter market (PINKSHEETS: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman’s scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company’s lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest.
SOURCE: Can-Fite
Post Views: 221
PETACH TIKVA, Israel I August 28, 2013 I Can-Fite BioPharma (TASE: CFBI) (PINKSHEETS: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it will initiate a its Phase 2 study in the U.S., Europe and Israel for its anti-cancer drug CF102 in the treatment of primary liver cancer (hepatocellular carcinoma, or HCC). CF102 is the second drug in the Company’s pipeline of A3 adenosine receptor ligands.
Based on the successful conclusion of a former Phase 1/2 trial, the Company developed a Phase 2 protocol that will be conducted under an open Investigational New Drug (IND) with the U.S. Food and Drug Administration. CF102 has Orphan Drug Designation from the FDA for the treatment of hepatocellular carcinoma (primary liver cancer).The study will include 130 patients with advanced liver cancer, with CF102 given as a standalone drug.
According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2 billion by 2015.
Data from the Phase 1/2 study were published recently in The Oncologist, one of the leading journals in this field, and will be presented in the 18th World Congress on Advances in Oncology. The Company reported that the Phase 1/2 study data demonstrated that the trial objectives were successfully achieved, demonstrating a very favorable safety profile for CF102 in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis classes A and B. In addition, the median overall survival time was very encouraging given that most patients were treated in the second-line setting and some were Child-Pugh class B. Another finding indicated that the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict the patients’ reaction to treatment with CF102. Interestingly, one of the patients that has been included in the Phase 1/2 study is treated for 4 years with CF102 and is doing very well.
About CF102
CF102 is a small orally bioavailable drug which binds with high affinity and selectivity to the A3 adenosine receptor. The latter is highly expressed in tumor cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. CF102 induces a robust anti-tumor effect via de-regulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells.
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American Depository Receipts of the company are traded on the over-the-counter market (PINKSHEETS: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman’s scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company’s lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest.
SOURCE: Can-Fite
Post Views: 221
